Applied Therapeutics Supports 15th Annual Rare Disease Day

Rhea-AI Summary

Applied Therapeutics (Nasdaq: APLT) is marking the 15th Annual Rare Disease Day to enhance awareness of rare diseases, specifically focusing on Galactosemia and SORD Deficiency. The company is actively supporting events like the GLOW for Galactosemia in Knoxville, Tennessee, and collaborating with advocacy partners on various initiatives. Its lead drug candidate, AT-007, aims to treat rare metabolic diseases with a high unmet medical need. The company emphasizes its commitment to developing solutions for these conditions, aligning with its clinical-stage development goals.

Positive

• Engagement in Rare Disease Day activities enhances brand visibility.
• AT-007 is in Phase 3 development, targeting diseases with no approved treatments.

Negative

• None.

NEW YORK, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today is recognizing the 15th Annual Rare Disease Day to help elevate awareness of rare diseases and call attention to the unique challenges facing people with rare diseases.

Applied Therapeutics is proud to support Rare Disease Day events across the U.S., including participating in the 5th Annual GLOW for Galactosemia Event in Knoxville, Tennessee, and virtually supporting GLOW teams across the country as they raise awareness of Galactosemia, a rare genetic metabolic disease resulting in an inability to metabolize the sugar galactose, which is found in foods and is also synthesized by the body. The company is collaborating with advocacy partners on a wide range of Galactosemia initiatives throughout the year, including Race 4 Jase and Fore Joey’s Cause. Applied Therapeutics is also partnering with the Charcot-Marie-Tooth Foundation and the Hereditary Neuropathy Foundation to raise awareness of SORD Deficiency, a rare disease which results in a progressive, debilitating hereditary neuropathy.

“We are pleased to support advocacy events such as GLOW for Galactosemia, and appreciate the tireless efforts of our advocacy partners, who raise awareness about the impact of rare diseases,” said Shoshana Shendelman, PhD, Founder and CEO of Applied Therapeutics. “We are committed to developing treatments for rare diseases with high unmet medical need, such as Galactosemia, SORD Deficiency and PMM2-CDG.”

About Rare Disease Day

Rare Disease Day takes place every year on the last day of February to raise awareness among the public and decision-makers about rare diseases and their impact on patients’ lives. It was established in 2008 by EURORDIS, the organization representing rare disease patients in Europe, and is now observed in more than 80 nations. In the U.S., Rare Disease Day is sponsored by the National Organization for Rare Disorders (NORD), the largest and leading independent, non-profit organization committed to the identification, treatment, and cure of rare diseases. For more information about Rare Disease Day in the U.S. and to search for information about rare diseases, visit NORD’s website, rarediseases.org/rare-disease-day.

About Applied Therapeutics

Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. Applied Therapeutics’ portfolio includes three Phase 3 programs for diseases with high unmet medical need and no approved treatment options. The Company’s lead drug candidate, AT-007, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Galactosemia and SORD Deficiency. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart.

To learn more, please visit www.appliedtherapeutics.com and follow the company on Twitter @Applied_Tx. A copy of the Company’s February 2022 Corporate Presentation is posted to the Investor Relations section of Applied Therapeutics’ website.

Contacts

Investors:
Maeve Conneighton, Eric Kasper
(212) 600-1902 or
appliedtherapeutics@argotpartners.com

Media:
media@appliedtherapeutics.com

FAQ

What is Applied Therapeutics' involvement in Rare Disease Day?

Applied Therapeutics is participating in Rare Disease Day events to raise awareness about rare diseases like Galactosemia and SORD Deficiency.

What rare diseases is Applied Therapeutics focused on?

The company is focused on Galactosemia and SORD Deficiency, which have high unmet medical needs.

What is the status of AT-007?

AT-007 is a lead drug candidate in Phase 3 clinical trials for treating Central Nervous System rare metabolic diseases.

When is Rare Disease Day celebrated?

Rare Disease Day is celebrated annually on the last day of February.

How is Applied Therapeutics supporting advocacy partners?

The company collaborates with advocacy partners to promote awareness and support initiatives for Galactosemia and SORD Deficiency.